Amorphous cyclosporin A nanoparticles for enhanced dermal bioavailability

International Journal of Pharmaceutics

Volumn 498, Issue 1-2, 2016, Pages 217-224

  Romero, Gregori B ^a   Arntjen, Anja ^b   Keck, Cornelia M ^b   Müller, Rainer H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES KAISERSLAUTERN   (Germany)

Author keywords

Amorphous; Cyclosporin A; Dermal; Nanocrystals; Nanoparticles; Nanosuspension

Indexed keywords

ALPHA TOCOPHEROL; CYCLOSPORIN A; HYDROXYPROPYLCELLULOSE; MACROGOL; NANOPARTICLE; POLYETHYLENE GLYCOL SUCCINATE; UNCLASSIFIED DRUG; WATER; CYCLOSPORIN;

ANIMAL TISSUE; ARTICLE; BEAD MILLING; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG STORAGE; EXPIRATION DATE; INVESTIGATIVE PROCEDURES; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER; PRIORITY JOURNAL; PSORIASIS; ROOM TEMPERATURE; SKIN PENETRATION; STRIPPING METHOD; SUSPENSION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; PIG; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; NANOPARTICLES; PARTICLE SIZE; SKIN ABSORPTION; SWINE;

EID: 84951178806     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.12.019     Document Type: Article

References (24)

1. Anger S., 2005. Field-Flow Fractionation: Basic Theory, Instrument Design and Pharmaceutical Applications. Doctoral Thesis, Freie Universität Berlin.
2. Auweter H., Bohn, H. Heger, R., Horn D., Siegel B., Siemensmeyer K., 2002. Precipitated water-insoluble colorants in colloid disperse form. US Patent 6494924.
3. P.R. Beauchesne, N.S. Chung, and K.M. Wasan Cyclosporine A: a review of current oral and intravenous delivery systems Drug Dev. Ind. Pharm. 33 2007 211 220
4. U. Blume-Peytavi, and A. Vogt Human hair follicle: reservoir function and selective targeting Br. J. Dermatol. 165 2011 13 17
5. J.D. Bos, and M.M. Meinardi The 500 Dalton rule for the skin penetration of chemical compounds and drugs Exp. Dermatol. 9 2000 165 169
6. Y. de Prost, D. Teillac, F. Paquez, L. Carrugi, H. Bachelez, and R. Touraine Placebo-controlled trial of topical cyclosporin in severe alopecia areata Lancet 2 1986 803 804
7. J.I. Duncan, S.N.L. Payne, A.J. Winfield, A.D. Ormerod, and A.W. Thomson Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity Br. J. Dermatol. 123 1990 631 640
8. A.F. Finzi, F. Ippolito, E. Panconesi, B. Giannotti, and A. Rebora Cyclosporin therapy in psoriasis: recommendations for treatment Dermatology 187 1993 38 40
9. Y. Guo, J. Luo, S. Tan, B.O. Otieno, and Z. Zhang The applications of Vitamin E TPGS in drug delivery Eur. J. Pharm. Sci. 49 2013 175 186
10. G. Ismailos, C. Reppas, J.B. Dressman, and P. Macheras Unusual solubility behaviour of cyclosporin A in aqueous media J. Pharm. Pharmacol. 43 1991 287 289
11. J.U. Junghanns, and R.H. Muller Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 3 2008 295 309
12. J. Lademann, H. Richter, A. Teichmann, N. Otberg, U. Blume-Peytavi, J. Luengo, B. Weiß, U.F. Schaefer, C.-M. Lehr, R. Wepf, and W. Sterry Nanoparticles - an efficient carrier for drug delivery into the hair follicles Eur. J. Pharm. Biopharm. 66 2007 159 164
13. D. Lechuga-Ballesteros, A. Abdul-Fattah, C.L. Stevenson, and D.B. Bennett Properties and stability of a liquid crystal form of cyclosporine - the first reported naturally occurring peptide that exists as a thermotropic liquid crystal J. Pharm. Sci. 92 2003 1821 1831
14. G. Levy, and K.E. Miller Drug absorption and exsorption kinetics in goldfish J. Pharm. Sci. 54 1965 1319 1325
15. Möschwitzer J., 2011. Method for producing ultrafine submicronic suspensions. Patent US8034381 B2.
16. A. Parodi, and A. Rebora Topical cyclosporine in alopecia areata Arch. Dermatol. 123 1987 165 166
17. A. Patzelt, H. Richter, F. Knorr, U. Schäfer, C.-M. Lehr, L. Dähne, W. Sterry, and J. Lademann Selective follicular targeting by modification of the particle sizes J. Control. Release 150 2011 45 48
18. M. Pikal, A. Lukes, and J. Lang Thermal decomposition of amorphous β-lactam antibacterials J. Pharm. Sci. 66 1977 1312 1316
19. J.M. Sowden, B.R. Allen, J. Berth-Jones, R.A.C. Graham-Brown, R.J. Motley, A.Y. Finlay, M. Salek, R. Marks, J.S. Ross, and R.D.R. Camp Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis Lancet 338 1991 137 140
20. J.M. Tam, J.T. McConville, R.O. Williams, and K.P. Johnston Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution J. Pharm. Sci. 97 2008 4915 4933
21. Troester F., Müller R.H., 2003. Nanopure, Nanocrystal Dispersions - Stabilization Principle For Water-sensitive Drugs, M1244, Annual Meeting of the American Association of Pharmaceutical Scientists (AAPS), Salt Lake City.
22. T. Van Joost, F. Heule, M. Korstanje, M.J.T.B. Van den Broek, H.J. Stenveld, and W.A. Van Vloten Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study Br. J. Dermatol. 130 1994 634 640
23. L. Yu Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv. Drug Deliv. Rev. 48 2001 27 42
24. Y. Zhou Cyclosporine A: solubilization, solid dispersion and solid-state transformation Doctoral Thesis 2000 Purdue University